Search Results - "PATY, D"

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses by O'CONNOR, P. W, LI, D, FREEDMAN, M. S, BAR-OR, A, RICE, G. P. A, CONFAVREUX, C, PATY, D. W, STEWART, J. A, SCHEYER, R

“…Teriflunomide, a dihydro-orotate dehydrogenase inhibitor, has immunomodulatory effects, including the ability to suppress experimental allergic…”
Get full text

Myelin water imaging in multiple sclerosis: quantitative correlations with histopathology by Laule, C, Leung, E, Li, D KB, Traboulsee, A L, Paty, D W, MacKay, A L, Moore, G RW

“…Various magnetic resonance (MR) techniques are used to study the pathological evolution of demyelinating diseases, such as multiple sclerosis (MS). However,…”
Get full text

Standardized MR imaging protocol for multiple sclerosis : Consortium of MS centers consensus guidelines by SIMON, J. H, LI, D, WOLINSKY, J. S, TRABOULSEE, A, COYLE, P. K, ARNOLD, D. L, BARKHOF, F, FRANK, J. A, GROSSMAN, R, PATY, D. W, RADUE, E. W

Get full text

Randomized controlled trial of interferon-beta-1a in secondary progressive MS : MRI results by LI, D. K. B, ZHAO, G. J, PATY, D. W

“…To examine MRI changes resulting from treatment of secondary progressive MS (SPMS) with two doses of interferon-beta-1a (Rebif). Interferon-beta (IFN-beta)…”
Get full text

Early onset multiple sclerosis: a longitudinal study by Boiko, A, Vorobeychik, G, Paty, D, Devonshire, V, Sadovnick, D

“…To evaluate the clinical course of MS in individuals with onset of MS before age 16. Patients with onset of MS before age 16 (n = 116) with complete clinical…”
Get full text

The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology by GOODIN, D. S, ARNASON, B. G, COYLE, P. K, FROHMAN, E. M, PATY, D. W

“…Mitoxantrone is the first drug approved for the treatment of secondary progressive multiple sclerosis (SPMS) in the United States. This assessment considers…”
Get full text

Dirty-appearing white matter in multiple sclerosis: Preliminary observations of myelin phospholipid and axonal loss by Moore, G. R. W., Laule, C., MacKay, A., Leung, E., Li, D. K. B., Zhao, G., Traboulsee, A. L., Paty, D. W.

“…“Dirty-appearing white matter” (DAWM) in multiple sclerosis (MS) is defined as a region(s) with ill-defined borders of intermediate signal intensity between…”
Get full text

The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis by FAZEKAS, F, BARKHOF, F, MILLER, D. H, FILIPPI, M, GROSSMAN, R. I, LI, D. K. B, MCDONALD, W. I, MCFARLAND, H. F, PATY, D. W, SIMON, J. H, WOLINSKY, J. S

“…MRI is very sensitive in showing MS lesions throughout the CNS. Using MRI for diagnostic purposes, however useful, is a complex issue because of limited…”
Get full text

A full genome search in multiple sclerosis by Ebers, George C, Kukay, Kim, Bulman, Dennis E, Sadovnick, Adele D, Rice, George, Anderson, Carol, Armstrong, Holly, Cousin, Keith, Bell, Robert B, Hader, Walter, Paty, Donald W, Hashimoto, Stanley, Oger, Joel, Duquette, Pierre, Warren, Sharon, Gray, Trevor, O'Connor, Paul, Nath, Avindra, Auty, Anthony, Metz, Luanne, Francis, Gordon, Paulseth, John E, Murray, T. John, Pryse-Phillips, William, Nelson, Robert, Freedman, Mark, Brunet, Donald, Bouchard, Jean-Pierre, Hinds, David, Risch, Neil

“…The aetiology of multiple sclerosis (MS) is uncertain. There is strong circumstantial evidence to indicate it is an autoimmune complex trait. Risks for first…”
Get full text

Depression and multiple sclerosis by SADOVNICK, A. D, REMICK, R. A, MORRISON, W, NELSON, J, OGER, J, PATY, D. W, ALLEN, J, SWARTZ, E, YEE, I. M. L, EISEN, K, FARQUHAR, R, HASHIMOTO, S. A, HOOGE, J, KASTRUKOFF, L. F

“…The objective of the present study were (1) to ascertain the lifetime risk of a depression in a representative group of multiple sclerosis (MS) patients, (2)…”
Get full text

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II: MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial by PATY, D. W, LI, D. K. B

Get full text

Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease by Brooks, D.J, Frey, K.A, Marek, K.L, Oakes, D, Paty, D, Prentice, R, Shults, C.W, Stoessl, A.J

“…A major goal of research in Parkinson's disease (PD) has been the development of treatments to slow the progressive degeneration of the nigrostriatal…”
Get full text

Recent developments in the assessment of quality of life in Multiple Sclerosis (MS) by Fischer, J S, LaRocca, N G, Miller, D M, Ritvo, P G, Andrews, H, Paty, D

“…Multiple sclerosis (MS) and its treatment have broad-ranging effects on quality of life. This article reviews recent efforts to assess the impact of MS on…”
Get full text

A pathology-MRI study of the short-T2 component in formalin-fixed multiple sclerosis brain by MOORE, G. R. W, LEUNG, E, PATY, D. W, MACKAY, A. L, VAVASOUR, I. M, WHITTALL, K. P, COVER, K. S, LI, D. K. B, HASHIMOTO, S. A, OGER, J, SPRINKLE, T. J

“…To determine the pathologic basis of areas not exhibiting signal of the short-T2 component of the T2 relaxation distribution in MS, as studied in…”
Get full text

In vivo measurement of T2 distributions and water contents in normal human brain by Whittall, K P, MacKay, A L, Graeb, D A, Nugent, R A, Li, D K, Paty, D W

“…Using a 32-echo imaging pulse sequence, T2 relaxation decay curves were acquired from five white- and six gray-matter brain structures outlined in 12 normal…”
Get more information

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis by McDonald, W. Ian, Compston, Alistair, Edan, Gilles, Goodkin, Donald, Hartung, Hans-Peter, Lublin, Fred D., McFarland, Henry F., Paty, Donald W., Polman, Chris H., Reingold, Stephen C., Sandberg-Wollheim, Magnhild, Sibley, William, Thompson, Alan, Van Den Noort, Stanley, Weinshenker, Brian Y., Wolinsky, Jerry S.

“…The International Panel on MS Diagnosis presents revised diagnostic criteria for multiple sclerosis (MS). The focus remains on the objective demonstration of…”
Get full text

Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis by Filippi, M, Horsfield, M A, Adèr, H J, Barkhof, F, Bruzzi, P, Evans, A, Frank, J A, Grossman, R I, McFarland, H F, Molyneux, P, Paty, D W, Simon, J, Tofts, P S, Wolinsky, J S, Miller, D H

“…The change of brain lesion load, measured on T2-weighted magnetic resonance imaging (MRI) using computer-assisted techniques, is a widely used secondary…”
Get more information

Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis : a follow-up study by FILIPPI, M, PATY, D. W, KAPPOS, L, BARKHOF, F, COMPSTON, D. A. S, THOMPSON, A. J, ZHAO, G. J, WILES, C. M, MCDONALD, W. I, MILLER, D. H

“…We obtained two conventional unenhanced T2-weighted brain MRI scans, separated by an interval of 24 to 36 months, in 281 patients with multiple sclerosis (MS)…”
Get full text

The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1b by RICE, G. P. A, PASZNER, B, OGER, J, LESAUX, J, PATY, D, EBERS, G

Get full text

Cause of death in patients attending multiple sclerosis clinics by Sadovnick, A D, Eisen, K, Ebers, G C, Paty, D W

“…Between 1972 and 1988, 145 deaths occurred among 3,126 patients attending the Multiple Sclerosis (MS) Clinics in Vancouver, British Columbia (N = 1,583), and…”
Get full text